Glucose & Insulin

Many with Type 2 Delay Insulin, to their Cost

More than 40% of people with type 2 diabetes initially decline insulin therapy recommended by their doctors, and compared with those who began insulin therapy, those who refused had worse glycemic control, and took longer to achieve healthier blood sugar levels , according to new research from Brigham and Women’s Hospital. Read more

Dexcom & DreaMed Diabetes to Collaborate on Insulin Delivery Platform

The collaboration enables a seamless data transfer of data from Dexcom’s CGM (continuous glucose monitoring) devices into DreaMed Advisor, a platform designed to assist healthcare professionals in the optimization of patient-specific insulin therapy for people with diabetes by analyzing information from CGM, self-monitoring blood glucose, and insulin delivery devices. Read more

Researchers See Paradox in Diabetes Management

Overtreatment and undertreatment can both pose serious problems for people with diabetes. It’s a fine line between enough treatment to prevent the complications caused by high blood sugars, and too much treatment, which can cause blood sugar levels to fall dangerously low (hypoglycemia). Individualized treatment could help avoid these issues. Read more

Coin-Sized Smart Insulin Patch Could Help Treat Diabetes

Researchers have made progress in developing a smart insulin-delivery patch that may one day monitor and manage glucose levels in people with diabetes, and deliver the necessary insulin dosage. The adhesive patch is about the size of a quarter, is simple to manufacture, and is intended for once-a-day use. Read more

Link Between Severe Low Glucose and Brain Health

Studies have shown that patients who have type 1 diabetes and severe hypoglycemia can experience a decrease in cognitive functions including visual perception, speed of information processing, attention span, psychomotor efficiency, and mental flexibility.  Read more

How can the High Cost of Insulin in the US be Brought Down?

Reducing the high cost of insulin in the United States will require multiple changes to the current complex drug pricing system, Mayo Clinic hematologist S. Vincent Rajkumar, MD, argues in a new commentary, The High Cost of Insulin in the United States: An Urgent Call to Action. Read more

Novo Nordisk Offers Free Insulin

Novo Nordisk has announced it would offer a free, one-time supply of insulin to people in immediate need and at risk of rationing the medication. Patients with prescription can get a free, one-time supply of up to three vials or two packs of pens of its insulin. Read more

FDA Approves Faster-Acting Insulin for Children

The U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection; Novo Nordisk), a rapid-acting human insulin analog, for use in children with diabetes. Fiasp has an additional ingredient, niacinamide, which increases absorption speed, and was previously approved for use in adults and in insulin pumps. Read more

FDA Approval for First Automated Insulin Dosing Controller

The Tandem t:slim X2 insulin pump will not only discontinue the delivery of insulin if blood sugars detected by a CGM record low blood sugars, but will also calculate the amount of insulin needed and inject that insulin when needed for elevated blood sugars. Read more

Oral Insulin May Soon Be Reality

A Phase 2b study in patients with type 2 diabetes (T2DM) was completed for what looks likely to be the first oral form of insulin (ORMD-0801). The developing company, Oramed Pharmaceuticals’, CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study discuss the results. Read more

Hospitals Fail to Implement Insulin Best Practices

According to recent research, greater than 75% of hospitals in the United States follow outdated insulin management protocols that are no longer recommended by the American Diabetes Association, American Association of Clinical Endocrinologists, and Society of Hospital Medicine. Read more

New Biosimilar Insulins May Be Coming, Thanks to FDA

A new US Food and Drug Administration (FDA) policy may help bring biosimilar insulins to market more quickly. (Biosimilars are biologic medical products that are highly similar to another already approved biological medicine.) However, analysts say there is no guarantee that the products will be significantly less expensive than branded insulins. Read more

Freestyle Libre Can Help People with Diabetes & Dementia

The FreeStyle Libre wearable monitor could be of great benefit in helping older people with diabetes and memory loss manage their condition better, according to researchers have said. The device automatically reads glucose levels without a fingerstick, making diabetes easier to manage. Read more

New Trial for Combination Therapy

The TTT-1 trial will begin in Scotland early in 2020 to assess a new combination therapy using insulin, dapagliflozin, and semaglutide. It is being led by Dr John Petrie from the University of Glasgow, a leading expert in the treatment of type 1 diabetes. The trial hopes the treatment will become a new option for […]

Circadian Clocks Disrupted by Glucose, Obesity

The circadian clocks inside the body’s cells that help regulate timing of many body functions and control cardiovascular disease risks within a 24-hour day appear to be affected by high glucose in obesity. “We know that high glucose impairs circadian clock functions, but now we want to know [if] by fixing the clock can we […]

U.N. Seeks to Address Rising Insulin Costs

The World Health Organization (WHO) has announced a plan to lower the “overly expensive” price of insulin. The agency, which is part of the United Nations, wants other drug companies to produce generic versions of insulin, which it will then test. Since its discovery in 1923, the price of insulin has risen in the United […]

CGMs Support “Time in Range” as New Standard

Fingerstick tests of blood sugar levels can tell patients what their blood sugar level is at any given moment, but not how consistent that level may be. CGMs can take nearly 300 blood sugar measurements a day, thus providing a new standard for measuring blood sugar control: time in range. Time in range refers to […]

Better Blood Sugar Control May Reduce Alzheimer’s Risk

People who have diabetes or metabolic syndrome (a group of risk factors that often precedes diabetes) are at almost double the risk for developing dementia. One possible cause, the way the brain metabolizes sugar, is now being explored by researchers. Read more

Why Aren’t More Patients Switching to Lilly’s Cheaper Insulin?

Eli Lilly introduced a generic version of Humalog at half the price, called insulin lispro, in March 2019. But this effort to make insulin more affordable may not be having that much of an impact for many people with diabetes, a data analysis shows. One reason is that the cheaper version isn’t actually cheaper, or […]

What is “Brittle” Diabetes?

Brittle diabetes — also called labile diabetes — is a term that describes particularly unstable type 1 diabetes; it typically refers to blood sugar (or blood glucose) levels that quickly swing from low (hypoglycemia) to high (hyperglycemia). Read more